Drug Trial Radar · NCT04158336
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
274
Actual
Start
Nov 1, 2019
Primary completion
May 6, 2025
Study completion May 6, 2025
Sponsor
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Conditions
- Solid Tumor
Interventions
AzenosertibDrug
Azenosertib (ZN-c3) is a study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose EscalationTime frame: Through completion, average of 1 year
- Food Effect CohortTime frame: Through completion, approx 6 months
- Food Effect CohortTime frame: Through completion, approximately 6 months
- Food Effect CohortTime frame: Through completion approximately 6 month
- Food Effect CohortTime frame: Through completion, approximately 6 mth
- Dose ExpansionTime frame: Through completion, approximately 43 month
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Site 0102
Tucson, Arizona
Site 0167
Newport Beach, California
Site 0171
Chicago, Illinois
Site 0101
Detroit, Michigan
Site 0173
New York, New York
Site 0179
Pittsburgh, Pennsylvania
Site 0103
Houston, Texas
Site 0100
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.